Demand for new and innovative drugs and widespread adoption of precision medicines is expected to boost the pharma industry. As the industry shows solid potential, quality pharma stock AbbVie Inc. (ABBV) might be a good value buy for August. However, it could be best to wait for a better entry point in Pfizer Inc. (PFE).
Customers in the pharmaceutical market are increasingly looking for personalized and targeted treatments with a focus on preventative healthcare. This has led to a rise in demand for precision medicines tailored to specific genetic profiles and offer more effective treatments with fewer side effects.
